Research Updates

“I am a researcher because I am driven to understand disease in order to treat it and be able to help people.” – Tonia Rex, PhD

Dr. Goldberg talks about the Catalyst for a Biomarker Imitative and its impact on glaucoma research.

Dr. Goldberg’s research is directed at neuroprotection and regeneration of retinal ganglion cells and the optic nerve, as well as stem cell and nanotherapeutic approaches to repair damaged eyes.

Researchers are working on some amazing things that artificial intelligence (AI) can do for glaucoma sufferers, especially in the areas of diagnosis and disease management, but it will take time and more work.

Matrix metalloproteinases (or MMPs) may sound like something out of a sci-fi story, but they’re a real-life family of enzymes—the metzincin superfamily—that thrive inside the human body.

Researchers are developing a new type of glasses that contain a prism that will redirect the sight of a person with limited peripheral vision.

Glaucoma causes damage to the optic nerve, which can result in an eventual loss of vision.

“What motivates me is the very real possibility of discovering something in my laboratory that can allow patients to see to see much better, for much longer periods of their life, and maybe even reverse blindness.”

Glaucoma doesn’t typically damage RPE cells, but thanks to advances in stem cell research, it looks like RPE cells may play a crucial role in finding a cure to the degenerative disease.

We are honored to introduce you to a prominent researcher whose work in glaucoma may one day lead to a cure: Dr. Richard Libby.

No one can predict the next big breakthrough in glaucoma treatment, but one thing is certain: A whole lot of experts are searching for ways to make the future better.

Catalyst for a Cure (CFC) is a collaborative team of investigators funded by Glaucoma Research Foundation.

In an attempt to demonstrate that low vision patients have good potential for overcoming vision loss, researchers undertook a study and presented their findings.

With exciting new biomarkers on the horizon, this is a good time to learn more about what they are and how they’ll ultimately help find a cure for glaucoma.

While this is a major breakthrough, OCT angiography must be improved before it will be ready for use in your doctor’s office.

Data published in October 2016 shows there is a successful, safe, routine surgical procedure that has been restoring eyesight for ages, and it may be the answer to treating primary closed-angle glaucoma (PCAG).

Catalyst for a Cure researchers have been taking necessary steps to move their studies from the laboratory to the clinic.

Nitric oxide has become a popular dietary supplement because it can help improve blood flow and lower blood pressure. As it turns out, nitric oxide also works as a glaucoma treatment.

Researchers are developing and validating new technologies that could enable less invasive approaches for vision prosthetics.

Optic nerve regeneration could be the answer to curing glaucoma, or at least substantially slowing the progression of the disease.

Stem cells are poised to make an impact on glaucoma research and treatment, as adult stem cells can be taken from the eye or skin, and used to try to replace damaged cells in your eye.

New contact lens technologies could make it easier for patients to comply with their medication plans and monitor both the progress of the disease and the efficacy of newly prescribed drugs.

A research study has found that high-contrast visual activity promotes optic nerve regrowth.

Nerve regeneration focuses on ways to regrow nerves. Neuroprotection is preventing the death of nerve cells. Both goals must be developed before vision loss due to glaucoma can be stopped or reversed.

What causes vision loss in glaucoma? First is elevated ocular pressure, and second is damage to the optic nerve, which is the structure that sends visual information to the brain.